Search

XL228

XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

BOS172722

The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects. … [A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123]

ISS-1018

ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. … It is also being investigated in combination with rituximab for treatment of b-cell or non-hodgkin's lymphoma.

Fibrinolysin

The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

AV608

AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

Apronalide

Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].

Cloxazolam

As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. … The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety.

Sulfobutylether-beta-cyclodextrin

Acifluorfen

Acifluorfen is a protoporphyrinogen oxidase inhibitor.

4-Nitrophenyl Phosphate